NCT04585776View on ClinicalTrials.gov

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

May 27, 2021

Study Completion Date

May 27, 2021

Conditions
Type 1 Diabetes
Interventions
DRUG

LY900014

Administered SC

DRUG

Insulin Degludec

Administered SC

Trial Locations (3)

30318

Atlanta Diabetes Associates, Atlanta

50265

Iowa Diabetes and Endocrinology Research Center, West Des Moines

55416

HealthPartners Institute dba International Diabetes Center, Minneapolis

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04585776 - A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes | Biotech Hunter | Biotech Hunter